Eli Lilly Stocks Rise 3.4% With Higher Sales but Lower EPS Guidance
Eli Lilly (LLY) raised its annual revenue guidance to $91B-$92B, up from $85B-$87B, but lowered its adjusted earnings guidance to $35-$36 per share. Shares rose 3.41% to $1,420.53 on October 30. Scotiabank increased its price target to $1,605, maintaining an Outperform rating. The changes reflect higher research spending due to acquisitions.
How this was made
The 30-second read
Why it matters
The mixed guidance creates a nuanced market reaction; investors weigh growth against profitability.
Market read
Guidance update is material for traders; the stock moved 3.4% on the news.
What to watch
Research spending may drive future pipeline value, not captured in the short‑term EPS guidance.
Background
Lilly announced Q3 results with higher revenue expectations but lower earnings per share guidance, prompting a modest stock rise.
Ticker impact
Eli Lilly raised its annual revenue guidance to $91‑$92 B while cutting adjusted EPS guidance to $35‑$36 per share, the first release of these numbers.
potential downside as the market prices in the lower earnings outlook
Revenue upside is modest (≈6%) while EPS is down ≈1.4%; investors may focus on earnings miss.
Market effects
Higher guidance may lift the broader pharma/biotech sector, but EPS cut could temper enthusiasm.
U.S. market focus on Lilly; limited immediate regional spillover.
Lilly’s guidance influences global diabetes/obesity drug outlook.
Counterpoint
The revenue boost could outweigh the modest EPS cut, supporting a short‑term rally.
Key entities
- companyEli Lilly
U.S. pharmaceutical company reporting guidance.
